About
Awards
History
Leadership
Board of Directors
Investors and Partners
Pipeline
Cefepime-Taniborbactam
Ceftibuten-Ledaborbactam Etzadroxil
PBP Inhibitor
Publications
Manuscripts
Conference Presentations
News & Events
Press Releases
In the News
Events
Careers
Open Positions
#venatorxcares
Contact
Publications
Publications
Manuscripts
Conference Presentations
Manuscripts
ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant
Pseudomonas aeruginosa
to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime
Examining the activity of cefepime-taniborbactam against
Burkholderia cepacia
complex and
Burkholderia gladioli
isolated from cystic fibrosis patients in the United States
MORE MANUSCRIPTS
Conference Presentations
In vitro activity of ceftibuten-ledaborbactam and comparators against Enterobacterales from a Phase 3 study of adults with complicated urinary tract infection (cUTI)
Outcomes at Test of Cure by baseline pathogen and cefepime-taniborbactam or meropenem MIC in the Phase 3 CERTAIN-1 study of patients with complicated urinary tract infection (cUTI)
In Vitro
Activity of Cefepime-Taniborbactamand Comparator Agents Against Gram-Negative Bacteria Isolated from Patients with Cancer
CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI)
MORE CONFERENCE PRESENTATIONS
You are using a browser that is not supported. Please consider changing your browser
